Journal article
NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma.
- Abstract:
-
BACKGROUND: Both oxaliplatin/capecitabine-based chemoradiation (OXCAP-RT) and carboplatin-paclitaxel based radiation (CarPac-RT) are active regimens in oesophageal adenocarcinoma, but no randomised study has compared their efficacy and toxicity. This randomised phase II "pick a winner" trial will identify the optimum regimen to take forward to a future phase III trial against neo-adjuvant chemotherapy, the current standard in the UK. METHODS/DESIGN: Patients with resectable adenocarcinoma of ...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
+ National Institute for Health Research Oxford Biomedical Research Centre
More from this funder
Funding agency for:
Mukherjee, S
+ CRUK Experimental Cancer Medicines Centre, Oxford
More from this funder
Funding agency for:
Mukherjee, S
+ National Institute for Health Research Oxford Biomedical Research Centre
More from this funder
Funding agency for:
Sharma, R
+ CRUK Experimental Cancer Medicines Centre, Oxford
More from this funder
Funding agency for:
Sharma, R
Expand funders...
Bibliographic Details
- Publisher:
- BioMed Central Publisher's website
- Journal:
- BMC cancer Journal website
- Volume:
- 15
- Issue:
- 1
- Pages:
- 1062
- Publication date:
- 2015-12-01
- DOI:
- EISSN:
-
1471-2407
- ISSN:
-
1471-2407
- Source identifiers:
-
510248
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:510248
- UUID:
-
uuid:68bd0c47-13aa-41a0-8cc0-56581a667247
- Local pid:
- pubs:510248
- Deposit date:
- 2015-11-20
Terms of use
- Copyright holder:
- Mukherjee et al
- Copyright date:
- 2015
- Notes:
-
Copyright © 2015 Mukherjee et al.; licensee BioMed Central.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record